Literature DB >> 9170631

Assessment, management, and prognosis of canine dominance-related aggression.

I R Reisner1.   

Abstract

Aggression directed toward owners is a common complaint, and one that causes a great deal of emotional conflict. Assessment and treatment of this disturbing behavior problem must address owner safety as well as realistic expectations for improvement. Relatively mild aggression may be treated with a combination of prevention of injury, increased structure in the home, and safe control of the dog, including obedience training to reward the dog for deference to the owner. Disproportionately severe or unpredictable aggression is less likely to respond to treatment. Mounting evidence exists that aggressiveness is genetically and neurobiologically driven. Research in other species, and early research in the dog, suggest that aggression may be reduced by drug therapy to modify brain neurochemistry. Such treatment is not a cure, however, and should be paired with a lifelong, systematic program of safety and control in the home.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9170631     DOI: 10.1016/s0195-5616(97)50050-7

Source DB:  PubMed          Journal:  Vet Clin North Am Small Anim Pract        ISSN: 0195-5616            Impact factor:   2.093


  2 in total

1.  The effect of citalopram hydrobromide on 5-HT2A receptors in the impulsive-aggressive dog, as measured with 123I-5-I-R91150 SPECT.

Authors:  K Peremans; K Audenaert; Y Hoybergs; A Otte; I Goethals; I Gielen; P Blankaert; M Vervaet; C van Heeringen; R Dierckx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-06       Impact factor: 9.236

2.  Estimates of regional cerebral blood flow and 5-HT2A receptor density in impulsive, aggressive dogs with 99mTc-ECD and 123I-5-I-R91150.

Authors:  Kathelijne Peremans; Kurt Audenaert; Frank Coopman; Peter Blanckaert; Filip Jacobs; Andreas Otte; Francis Verschooten; Henri van Bree; Kees van Heeringen; John Mertens; Guido Slegers; Rudi Dierckx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-03       Impact factor: 9.236

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.